Long-term treatment with proton pump inhibitor is associated with undesired weight gain

World Journal of Gastroenterology

Volumn 15, Issue 38, 2009, Pages 4794-4798

  Yoshikawa, Ichiro ^a   Nagato, Makiko ^a   Yamasaki, Masahiro ^a   Kume, Keiichiro ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Body weight; Gastroesophageal reflux disease; Proton pump inhibitor

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

AGED; ARTICLE; BLOOD PRESSURE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIET; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; LIFESTYLE MODIFICATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL PARAMETERS; SIDE EFFECT; WEIGHT GAIN;

EID: 73449107449     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4794     Document Type: Article

References (26)

1. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-1456
2. Hampel H, Abraham NS, El-Serag HB. Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 2005; 143: 199-211
3. Kitchin LI, Castell DO. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991; 151: 448-454
4. Metz DC. Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med 2004; 117 Suppl 5A: 49S-55S
5. Neumayer C, Ciovica R, Gadenstätter M, Erd G, Leidl S, Lehr S, Schwab G. Significant weight loss after laparoscopic Nissen fundoplication. Surg Endosc 2005; 19: 15-20
6. Anjiki H, Sanaka M, Kuyama Y. Dual effects of rabeprazole on sol id-phase gastric emptying assessed by the 13C-octanoate breath test. Digestion 2005; 72: 189-194
7. Benini L, Castellani G, Bardelli E, Sembenini C, Brentegani MT, Caliari S, Vantini I. Omeprazole causes delay in gastric emptying of digestible meals. Dig Dis Sci 1996; 41: 469-474
8. Rasmussen L, Oster-Jørgensen E, Qvist N, Pedersen SA. The effects of omeprazole on intragastric pH, intestinal motility, and gastric emptying rate. Scand J Gastroenterol 1999; 34:671-675
9. Tougas G, Earnest DL, Chen Y, Vanderkoy C, Rojavin M. Omeprazole delays gastric emptying in healthy volunteers: an effect prevented by tegaserod. Aliment Pharmacol Ther 2005; 22: 59-65
10. Lewis SJ, Franco S, Young G, O'Keefe SJ. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10:557-561
11. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 512-519
12. Kim BW, Lee BI, Kim HK, Cho YS, Chae HS, Lee HK, Kim HJ, Han SW. [Influence of long-term gastric acid suppression therapy on the expression of serum gastrin, chromogranin A, and ghrelin] Korean J Gastroenterol 2009;53: 84-89
13. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100: 190-200
14. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965-971
15. Fraser-Moodie CA, Norton B, Gornall C, Magnago S, Weale AR, Holmes GK. Weight loss has an independent beneficial effect on symptoms of gastro-oesophageal reflux in patients who are overweight. Scand J Gastroenterol 1999; 34: 337-340
16. Jacobson BC, Somers SC, Fuchs CS, Kelly CP, Camargo CA Jr. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354: 2340-2348
17. El-Serag HB, Graham DY, Satia JA, Rabeneck L. Obesity is an independent risk factor for GERD symptoms and erosive esophagitis. Am J Gastroenterol 2005; 100: 1243-1250
18. Nilsson M, Johnsen R, Ye W, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290: 66-72
19. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999; 106: 642-649
20. Kulig M, Nocon M, Vieth M, Leodolter A, Jaspersen D, Labenz J, Meyer-Sabellek W, Stolte M, Lind T, Malfertheiner P, Willich SN. Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. J Clin Epidemiol 2004; 57: 580-589
21. Murray L, Johnston B, Lane A, Harvey I, Donovan J, Nair P, Harvey R. Relationship between body mass and gastrooesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol 2003; 32: 645-650
22. Stanghellini V. Three-month prevalence rates of gastrointestinal symptoms and the influence of demographic factors: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999; 231: 20-28
23. Wu AH, Tseng CC, Bernstein L. Hiatal hernia, reflux symptoms, body size, and risk of esophageal and gastric adenocarcinoma. Cancer 2003; 98: 940-948
24. Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, Locke GR 3rd, Rodriguez-Artalejo F. Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 2004; 19: 95-105
25. Overweight, obesity, and health risk. National Task Force on the Prevention and Treatment of Obesity. Arch Intern Med 2000; 160: 898-904
26. Blair DI, Kaplan B, Spiegler J. Patient characteristics and lifestyle recommendations in the treatment of gastroesophageal reflux disease. J Fam Pract 1997; 44: 266-272